Wilex Delays Raising €14M After Good Data on Antibody
BioWorld International Correspondent
Wilex AG delayed completion of a capital increase because of the early arrival of positive preliminary data from a Phase III trial of its diagnostic antibody Redectane, which is in development for presurgical detection of clear cell renal cell carcinoma, the most common form of kidney cancer.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST